Although type I interferon response is predominant in DM, EBV’s latent membrane protein 1 (LMP1) can inhibit IFN-stimulating genes (ISGs) expression by blocking interferon regulatory factor 5 (IRF5) and STAT transcription factors. The gene discussed is IRF5; the disease is dermatomyositis.